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INTRODUCTION
Obstetrician/Gynecologists often provide care to women
over the course of their lifetime, typically from the
reproductive age through menopause. Conditions for
which screening is indicated vary in different lifetime
intervals. This poster presents an overview of the optimal
screening tools for the most prominent GYN conditions.
Screening is defined as appropriate testing in
asymptomatic patients who may have a pertinent
prevalence of a condition. On the contrary, if a patient has
symptoms, testing to reveal a diagnosis is indicated. Each
of the following scenarios represent instances of
screening procedures performed for the detection of
relevant conditions.

MATERIALS and METHODS
The following routine clinical scenarios were reviewed, to
report the apparent incidence of these practical behaviors
and the results of finding the pathologic conditions for
which such screening is performed. The medical literature
was mined to determine the extent of each described
pattern.
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Infectious Conditions:

Cervical Cancer Screening:

Though there are many commonly presenting sexually
transmitted pathogens, Chlamydia trachomatis often
causes asymptomatic cervicitis. Fifteen percent of girls
and women between the ages of 16 and 24 are found to
have C. trachomatis by polymerase chain reaction (PCR)
testing. 1 C. trachomatis cervicitis can lead to PID in 22 %
of cases. 2 For this reason, such cervical testing may be
considered during a pelvic examination even in the
absence of the presence of cervical exudate.

Exfoliative cytology of the uterine cervix using the
Papanicolaou staining technique (the “Pap Smear”) has
been used for more than half a century, to screen for
cervical cancer precursors. Testing for high-risk Human
Papillomavirus (HPV) serotypes has been considered as a
screening replacement for this. The use of Cervical Cancer
Screening, with whichever of these tools, has reduced the
incidence of cervical cancer mortality by 70% over the
past half century. 3

The number of cases of Chlamydial cervicitis was 1.7
million in 2018 in the U.S. 4 Much evidence has linked
untreated Chlamydial cervicitis with the incidence of PID,
and it can be estimated that 170,000 of such cases may
have been prevented.

Pregnancy-related:
Many pregnancy-related conditions are routinely
screened for with prenatal laboratory testing. One
currently important condition, preeclampsia, can be
considered for screening to find historical predictors of
preeclampsia, as it appears that administration of lowdose aspirin (LDA) may have prophylactic value.
Among the approximately 3.8 million certificates of live
births in 2018 reported by the National Center for Health
Statistics (NCHS), there was a 4.6% prevalence of
preeclampsia, for which LDA can be considered for
prophylaxis when specific risk factors indicate its use in
pregnancy. 6 It is possible, therefore, that over 10,000
cases of preeclampsia and its associated preterm births
may have been prevented with antepartum LDA.
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In 2016, there were 22.6 million pap smears performed,
and over 22,000 cases of cervical cancer recorded.
Presumably, a portion of those may have prevented with
treatable precursors (e.g., CIN III) with pap smear (or
alternative) screening prior to that diagnosis. 7 Hence, the
specific preventative value of cervical cancer screening
can potentially be estimated.

Other GYN Cancers:
The number of patient encounters for which ultrasound
examinations were performed for screening of ovarian or
endometrial cancer could not be easily quantified in this
investigation. However, if no specific complaints are
offered during a well woman ambulatory visit, but during
the bimanual examination conducted at the time, an
adnexal mass is encountered, further examination may be
in order.
If the International Ovarian Tumor Analysis (IOTA)
protocol 8 is followed, as is becoming more
commonplace, the early diagnosis of ovarian cancer may
be determined in 25% of cases undergoing transvaginal
sonography (TVUS) and biomarker detection (CA 125). 9
There were over 22,000 new cases of ovarian cancer
diagnosed in 2018, usually at Stage 3 or higher, with over
14,000 deaths recorded. 10 This may indicate the value of
bimanual examination screening for ovarian tumors.

CONCLUSIONS
As can be seen by these clinical scenarios,
Obstetricians/Gynecologists routinely perform
screening procedures in clinical practice, thereby
diagnosing and treating a variety of conditions,
often successfully eliminating clinical problems
that would otherwise be expressed without such
screening. This represents an important aspect of
modern OB/GYN clinical practice, illustrated here.
A recently published well-articulated and valid
commentary 11 described barriers to epidemiologic
research in this clinical health area, primarily
speaking to non-cancerous disease diagnosis and
treatment. However, this poster recognizes
substantial community health benefit resulting
from ordinary routine obstetric/gynecologic
practice, relating to both benign and malignant
disease. The overlap of infectious disease (e.g., HPV
transmission) and cervical cancer is especially
pertinent, as it relates to cervical malignancy.
Epidemiologic research in Obstetrics and
Gynecology is still possible from the data collection
which is currently in place, and we look forward to
additional elements which furthers this effort.
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